Sanofi's most immediate and dangerous challenge is its extraordinary dependence on a single product: Dupixent generated $14.3 billion in FY2024 sales, representing 31.8% of total company revenue and 93.4% of the immunology segment. This concentration creates existential vulnerability. While Dupixent's patent protection extends into the 2030s and the company is actively developing new indications—including chronic pruritus of unknown origin and lichen simplex chronicus—the eventual entry of biosimilar competitors would devastate Sanofi's revenue base if replacement products are not established. The company has acknowledged this risk explicitly, with CEO Paul Hudson stating that Sanofi is 'wary of its outlook becoming too reliant on sales for the product.' The second critical challenge is the structural decline of the General Medicines portfolio, which contributed 20.0% of revenue in 2024 but faces continuous erosion from generic competition. Lantus, once generating $6.5 billion annually, now produces $1.7 billion and continues to decline. Aubagio faces generic competition in multiple sclerosis. The entire General Medicines segment requires active management to extract remaining value while preventing resource drain. Third, Sanofi's vaccine division—while historically a strength and the world's largest dedicated vaccine business—faces pricing pressure and competitive threats. The influenza vaccine market is increasingly crowded, with Sanofi competing against GSK, Seqirus, and others. The pediatric vaccine market faces pricing pressure from government procurement. Beyfortus, while successful, now faces competition from MSD's Enflonsia (clesrovimab), approved in 2025. The COVID-19 pandemic disrupted vaccination routines and created demand volatility that continues to affect scheduling and inventory management. Fourth, the Dengvaxia controversy in the Philippines caused lasting reputational damage and contributed to vaccine hesitancy that extended beyond dengue to measles and COVID-19 immunization programs. The Philippine FDA permanently revoked Dengvaxia's license in February 2019, and criminal investigations into Sanofi executives continue. While the vaccine remains approved in the US, EU, and other markets for previously exposed individuals, the controversy exemplifies how a single safety signal can cascade into geopolitical and commercial crises in emerging markets. Fifth, Sanofi faces intense competition across all therapeutic areas. In immunology, Dupixent competes against AbbVie's Rinvoq, Eli Lilly's Olumiant, and Pfizer's Xeljanz in various indications, though Dupixent's biologic positioning and safety profile maintain differentiation. In rare diseases, Takeda, Alexion (AstraZeneca), and BioMarin are aggressive competitors. In oncology, Sanofi is a relatively small player compared to Merck, Bristol Myers Squibb, and AstraZeneca, requiring significant investment to build competitive positioning. Sixth, the planned separation of Opella creates execution risk. While the consumer healthcare unit is non-core to the biopharma strategy, the separation requires careful management of transition services, employee retention, and financial restructuring. Any delay or valuation disappointment would undermine investor confidence. Seventh, Sanofi faces regulatory and pricing pressure globally. In the US, the Inflation Reduction Act's Medicare drug price negotiation program could eventually affect Dupixent's pricing power. In China, volume-based procurement and national reimbursement drug list changes create pricing volatility, as evidenced by the 10.4% Q4 2024 sales decline attributed to inventory effects ahead of reimbursement changes. In Europe, reference pricing and health technology assessment requirements continue to constrain pricing flexibility. Eighth, the company's R&D productivity remains under scrutiny. Despite $8.1 billion in annual investment, Sanofi has faced setbacks in oncology and cardiovascular programs, requiring active portfolio prioritization to focus on best-in-class or first-in-class assets. The 2025 acquisition of Blueprint Medicines for $9.5 billion represents a significant bet on precision oncology that must deliver clinical and commercial success to justify the premium paid.